12 Longevity Clinics and Treatments That Aim to Extend Human Lifespan

Longevity clinics promise more than wrinkle reduction or simple wellness checks. They package science-forward testing, personalized plans, and a mix of established and experimental therapies aimed at keeping people healthier for longer. Some clinics focus on detailed laboratory work—genomic sequencing, proteomics, methylation clocks—while others layer in metabolic therapies, IV regimens, or cutting-edge approaches inspired by laboratory breakthroughs. That blend creates a wide spectrum: on one end are conservative practices that offer lifestyle, screening, and evidence-based preventive care; on the other are high-cost, experimental programs that lean on early-stage biotech advances. Readers should expect transparency and clear statements about what is proven and what remains investigational. Across the field, costs can be steep and access uneven; one clinic model reported an annual fee around $19,000, which highlights an ongoing equity issue. Regulation also varies by country, so what’s offered in one place may be tightly restricted elsewhere. This piece walks through 12 clinic types, companies, and treatment approaches you’ll see in the longevity world. Each item explains the science level, what patients commonly experience, questions to ask, and practical considerations—so you can approach this emerging space with curiosity and healthy caution.

1. Human Longevity Inc. clinic model

Human Longevity Inc. exemplifies the high-touch, data-rich clinic approach some patients choose when they want a deep health baseline and ongoing monitoring. Reports indicate a comprehensive annual program can cost roughly $19,000 per year, which typically covers extended lab panels, genomic sequencing, detailed metabolic testing, clinician time, and personalized lifestyle plans. Those services are attractive because they promise a thorough snapshot of current health and potential risk factors that standard primary care may not capture. That said, a major limitation is translating dense test results into interventions proven to lengthen life expectancy. Some findings inform well-supported preventive steps—like blood pressure control, statin recommendations, or exercise plans—while other insights, such as certain epigenetic markers, remain research signals rather than clear treatment targets. For prospective patients, clarity matters: ask the clinic which services are evidence-based, which are exploratory, and what outcomes they can document. Also inquire about data privacy and how your genomic data will be stored or used. A careful, transparent clinic will help you prioritize high-value actions first and treat experimental options as optional adjuncts rather than primary solutions.

2. Altos Labs — research-to-clinic ambitions

Altos Labs is one of the best-known names in longevity biotech because of its unusually large early funding and high-profile leadership. The company invests heavily in cellular reprogramming research—work that aims to reset cells to a younger-like state by manipulating gene expression. Most activity today is preclinical; the breakthroughs reported in animal models are scientifically exciting and drive investor interest, but they’ve not yet translated into widely available human treatments. Clinics that reference this kind of work may offer informed interpretations or pilot programs, but patients should understand the difference between lab-stage discoveries and proven clinical therapies. If a clinic claims to use direct Altos Labs protocols in patient care, ask for peer-reviewed evidence and clear safety data. For most people, Altos Labs’ role in the ecosystem is as a research engine: its publications and patents will likely influence future clinical trials and, eventually, regulated therapies. For now, the company’s public profile helps explain why longevity medicine is attracting resources and attention, but it does not mean safe, validated age-reversal treatments are yet on offer for consumers.

3. Epigenetic reprogramming (Yamanaka factors)

Epigenetic reprogramming traces back to Shinya Yamanaka’s discovery that a set of transcription factors can reset a cell’s identity. In partial reprogramming, researchers aim to roll back cellular aging markers without losing cell specialization. Animal studies have shown promising lifespan and healthspan effects when reprogramming is tightly controlled. Clinics referencing this science may emphasize its potential to address age-related decline at a foundational level, but important safety questions remain for humans—most notably, how to prevent cells from becoming pluripotent in ways that raise cancer risk or tissue dysfunction. Regulatory agencies are focused on clear safety signals before approving human treatments that alter cellular identity, so anything offered now in a clinical setting should be treated as experimental and confined to formal trials. Prospective patients should ask whether proposed interventions are part of registered clinical trials, what endpoints are being measured, and what independent oversight exists. Right now, partial reprogramming is an exciting research avenue with real promise, but it’s not yet a standard clinical therapy you can safely access outside tightly controlled studies.

4. Senolytic therapies

Senolytics target senescent cells—cells that have stopped dividing and secrete inflammatory signals that can harm nearby tissue. In lab models, clearing these cells has improved organ function and increased healthy lifespan markers. A number of clinical trials are testing different senolytic drugs and repurposed compounds, and some clinics have begun offering off-label regimens or experimental protocols under physician oversight. That practice sits in a grey zone: patients may access potential benefits sooner, but they also assume risks that formal trials exist to quantify. Common safety concerns include unintended effects on tissue regeneration and immune responses. If a clinic recommends senolytic treatment, ask whether the protocol is part of a trial, whether baseline and follow-up measures will be taken, and how adverse events are tracked. Look for transparency about which drugs are proven for specific conditions and which are speculative. Right now, senolytics are one of the most active translational areas in longevity science—promising, but not yet a universal, proven clinical standard.

5. NAD+ and metabolic therapies

NAD+ supplements and IV therapy have become popular in some longevity circles because NAD+ is a key metabolite tied to cellular energy and repair. Clinics offering NAD+ infusions often pair them with metabolic reset programs—diet guidance, exercise prescriptions, and hormone optimization. The biological rationale is plausible: NAD+ levels decline with age, and boosting them may improve cellular resilience. Clinical evidence, however, is mixed. Some small studies show metabolic or subjective benefits, while larger, long-term trials connecting NAD+ therapies to meaningful lifespan or major disease outcomes are still limited. Cost is a practical consideration—IV regimens and ongoing infusions can add up quickly with unclear return on investment. For patients, an evidence-first approach helps: prioritize lifestyle changes with proven benefits, view NAD+ as a potential adjunct, and ask any clinic for trial data, expected benefits, and clear monitoring protocols. If the clinic recommends frequent IVs, ask about sterility procedures, medical oversight, and whether less invasive NAD+ boosters have been considered first.

6. Stem-cell–based interventions

Stem-cell therapies cover a broad range of approaches, from FDA-approved uses like certain bone marrow transplants to less-regulated offerings for joint pain, cosmetic issues, or broader “rejuvenation” aims. Many clinics promote mesenchymal stromal cell (MSC) injections for tissue repair or immune modulation; the quality of evidence varies by indication. Where strong randomized trials exist, clinicians can recommend cell therapies with confidence. Where evidence is thin, patients may pay for interventions that deliver unclear benefit and bear potential safety risks like infection or aberrant tissue growth. Regulation matters: in the US, the FDA scrutinizes claims and may require an approved pathway for most stem-cell products. Ask a clinic whether a therapy is FDA-approved for your condition, whether the offering is part of a clinical trial, and to see peer-reviewed data. Also request details on cell sourcing, processing, sterility, and follow-up plans. When used appropriately and transparently, stem-cell treatments can be powerful. When used prematurely, they risk harm and costly disappointment.

7. Telomere diagnostics and interventions

Telomere length has been proposed as a biological marker of cellular aging, and some clinics offer telomere testing as part of a longevity profile. In research settings, very short telomeres associate with certain diseases, but telomere length alone is not a definitive predictor of lifespan for an individual. Interventions aimed at lengthening telomeres, including telomerase upregulation, are under study. While early lab results suggest possible benefits, clinical evidence tying telomere interventions to meaningful, safe life extension in humans is limited. Patients should treat telomere testing as one data point among many and avoid clinics that promise dramatic reversal of aging based solely on telomere numbers. If a clinic proposes telomerase-based therapy, request peer-reviewed safety data, long-term monitoring plans, and transparent explanation of expected outcomes. In short, telomere science is fascinating and offers potential biomarkers, but it’s not a standalone roadmap to guaranteed longevity.

8. Genomic, proteomic and multi-omic profiling

Multi-omic profiling—combining genomics, proteomics, metabolomics, and epigenetic clocks—gives clinics a rich dataset to personalize recommendations. Methylation-based epigenetic clocks can estimate biological age and track changes over time, and proteomic or metabolomic snapshots can highlight metabolic imbalances. These tools can uncover actionable issues like undetected prediabetes or inflammatory patterns that respond to diet, exercise, or medication. But the predictive power of multi-omics for individual lifespan remains imperfect; many signals point to risk trends rather than definitive outcomes. The real value is for personalized prevention: targeted screenings, risk-adjusted screening intervals, and tailored lifestyle recommendations. When considering multi-omic testing, ask a clinic how results will change care, whether interventions reduce validated endpoints, and how often repeat testing is recommended. Data privacy is also a central concern—request written policies about data use, sharing, and de-identification before consenting to broad molecular profiling.

9. Concierge longevity practices and personalized plans

Concierge longevity clinics bundle personalized care with easy access: longer appointments, proactive follow-ups, and a focus on wellness optimization. Members often receive annual or semiannual full-day assessments, access to a care team, and quick adjustments to plans. This model can improve adherence and give time to address complex questions that matter for long-term health. The downside is price: memberships and proprietary testing can be costly, and benefits depend heavily on clinician expertise and the clinic’s commitment to evidence-based care. Prospective members should evaluate the team’s credentials, exam what is covered versus billed separately, and verify whether services rely on proven interventions or experimental offerings. Also ask about integration with your primary care—coordinated care is safer than fragmenting responsibility. For many, concierge models raise the standard of preventive attention; for others, the cost-benefit ratio may not justify the expense if similar preventive actions are available through existing healthcare channels.

10. International hubs and regulatory differences

Longevity science is global, and regulatory frameworks vary widely. Some countries encourage fast translation of lab discoveries to clinical settings, while others require more stringent trials before patient access. Recent reporting highlights large-scale initiatives and private hubs in places like China that pursue ambitious aging projects, sometimes with a mix of rigorous science and promotional claims. That contrast matters: a therapy available in one country may be restricted or unapproved elsewhere. Travel for treatment can expose patients to differing standards of care, varying follow-up quality, and legal recourse limitations. If travel is being considered, evaluate the clinic’s regulatory oversight, accreditation, and published outcomes. Check whether protocols are part of registered trials and whether international staff publish peer-reviewed results. Global innovation can accelerate access to new ideas, but it also raises questions about consistent safety standards, informed consent in different languages or cultures, and long-term data collection across borders.

11. Costs, access, and ethical concerns

Cost is a defining feature of modern longevity care. Comprehensive programs and membership models can reach tens of thousands per year, creating an environment where the latest interventions may be accessible mainly to the well-off. That raises ethical issues around equity and the potential for a two-tiered system in which wealthy individuals access experimental or early-stage therapies not yet validated for wider use. Transparency around pricing and expected outcomes is crucial. Clinics should provide clear fee schedules, explain what’s standard care versus experimental, and document outcomes in a way that permits independent assessment. Data ownership is another ethical front: patients should know how their biological and genomic data will be used, shared, or monetized. Finally, there’s a public health angle—rapid adoption of unproven therapies can complicate regulation and skew research priorities. Asking about affordability programs, trial participation options, and whether the clinic contributes data to independent registries can help patients align their choices with ethical standards they feel comfortable supporting.

12. What patients should expect and ask

Visiting a longevity clinic should start with clear goals, realistic expectations, and safety-first thinking. Expect a baseline assessment: medical history review, labs, and often multi-omic tests. Good clinics prioritize interventions with demonstrated benefits—vaccination, blood pressure control, cholesterol management, smoking cessation—while framing experimental options separately. Before proceeding, ask whether a proposed therapy is part of a registered clinical trial, what evidence supports it, and what side effects or long-term risks are known. Clarify credentials for the treating team, data privacy policies, and how results will be communicated and integrated with your primary care. Request written informed consent for experimental treatments and a plan for follow-up care if complications arise. Finally, ask about measurable goals: which biomarkers or clinical outcomes will be tracked, and how success will be defined. When clinics answer these questions clearly, patients can make informed choices that balance hope with the hard work of safe, evidence-driven care.

Takeaway: How to approach longevity clinics with curiosity and caution

Longevity clinics sit at the intersection of exciting science and practical healthcare decisions. Some services genuinely extend standard preventive care with a useful, personalized lens—detailed testing, focused risk reduction, and lifestyle programs that improve daily function and disease prevention. Other offerings lean on early-stage science or experimental protocols that will need more rigorous trials to prove safety and benefit. The right approach is balanced: stay curious about promising research, but insist on evidence, transparency, and safety. Ask clinics whether a treatment is experimental or established, how outcomes are measured, and who is responsible for follow-up care. Prioritize basic, high-value steps that have clear public health benefits—vaccination, exercise, healthy diet, blood pressure and lipid control—then consider innovative therapies as complementary options when they are available through well-designed trials. Aging thoughtfully is not about chasing miracles; it’s about making informed choices that support longer, healthier years. With clear questions and a priority on proven actions, you can move forward in this new medical landscape with both hope and healthy skepticism.